team news

May 15, 2018

Publication including Exscientia's chief chemist Andy Bell, describes a potential new treatment for the common cold

Exscientia is delighted to note that its Chief Chemist Andy Bell, who previously led a medicinal chemistry team at Imperial College, has published ground-breaking work that identifies novel molecules to treat the common cold.

The research, published in Nature Chemistry, describes work behind the design of IMP-1088, a novel and highly potent anti-viral that prevents the cold virus from making new copies of itself. By targeting a human protein (N-myristoyltransferase) rather than a cold virus protein, the emergence of drug resistance to IMP-1088 is expected to be minimised. Further research leading to human clinical trials is anticipated.
To learn more, see the announcement by Imperial College and the original publication.

Liked the article? Let’s share it!